Study procedures
TRAEs, Cancer
ADVERSE EVENT, ADVERSE EVENTS, ADVERSE EFFECTS, SURGICAL COMPLICATIONS, CANCER
Eligible patients agreed to written informed consent before enrollment and were assigned to receive adjuvant immunotherapy following esophagectomy after nICT. All patients received neoadjuvant immunotherapy (tislelizumab 200 mg d1, q3w× 2 cycles) and chemotherapy (nad-paclitaxel 260 mg/mTreatment could be interrupted or postponed if any serious adverse effects occured, and treatment could be resumed until the established standards for resumption of treatment were met. The safety-related endpoints included neoadjuvant and adjuvant treatment-related adverse events (TRAEs), immune-related adverse events (irAEs), resection rate, and surgical complications. TRAEs and irAEs were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE5.0) [The enrolled patients received thoracoscopy combined with laparoscopy -assisted esophagectomy using the McKeown procedure, including thoraco-abdominal two-field lymphadenectomy.The lymph node stations dissected were as follows [